68 Ga-somatostatin receptor analogs and 18 F-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis

Abstract

Background

Metastatic pheochromocytoma and paraganglioma (PCs/PGLs) show high germline mutation, and ¹⁸F-FDG and ⁶⁸Ga-DOTA peptide positron emission tomography/computed tomography (PET/CT) imaging are recommended for the diagnosis of metastatic of PCs. However, there has been lack of direct comparison of the two modalities in the diagnosis of metastatic of PCs up to now.

Purpose

To evaluate and compare the value of localization of ⁶⁸Ga-somatostatin receptor analogs and ¹⁸F-FDG in the diagnosis of metastatic PCs/PGLs.

Material and Methods

A comprehensive literature search of PubMed/MEDLINE, ScienceDirect, and Web of Science was performed in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines published in August 2016. We critically reviewed all studies based on the PICOS criteria. QUADAS-2 was used to evaluate the quality of the methodology of the included studies.

Results

This meta-analysis included 17 studies (629 patients, average age [mean ± SD] = 42.7 ± 6.3 years). The pooled sensitivity and specificity of ¹⁸F-FDG and ⁶⁸Ga peptides were 0.85 (95% confidence interval [CI] = 0.78–0.91) and 0.55 (95% CI = 0.37–0.73), and 0.95 (95% CI = 0.92–0.97) and 0.87 (95% CI = 0.63–0.96), respectively. The area under the sROC curves of the ¹⁸F-FDG and ⁶⁸Ga peptides were 0.88 (95% CI = 0.85–0.91) and 0.78 (95% CI = 0.74–0.81), respectively. A subgroup analysis demonstrated that the difference at the per-lesion level and gene mutation level was significant.

Conclusion

Compared to ¹⁸F-FDG PET/CT, the ⁶⁸Ga-somatostatin receptor demonstrated good performance in the localization of metastatic PCs/PGLs, especially those with germline mutations. The use of the ⁶⁸Ga-somatostatin receptor can be a new tool in the diagnosis of metastatic PCs/PGLs.